HOME >> BIOLOGY >> NEWS
Universal flu vaccine being tested on humans

Ghent, Belgium -- A universal influenza vaccine that has been pioneered by researchers from VIB and Ghent University is being tested for the first time on humans by the British-American biotech company Acambis. This vaccine is intended to provide protection against all A strains of the virus that causes human influenza, including pandemic strains.

Flu

Influenza is an acute infection of the bronchial tubes and is caused by the influenza virus. Flu is probably one of the most underestimated diseases: it is highly contagious and causes people to feel deathly ill. An average of 5% of the worlds population is annually infected with this virus. This leads to 3 to 5 million hospitalizations and 250,000 to 500,000 deaths per year. In Belgium, an average of 1500 people die of flu each year. A more severe flu year - such as the winter of 1989-1990 - claimed in our country 4500 victims. Besides the annual flu epidemics, there is the possibility of a pandemic, which occurs every 10 to 30 years and causes more severe disease symptoms and a higher mortality rate. During the pandemic caused by the Spanish flu in 1918-1919, the number of deaths worldwide even rose to over 50 million.

Why an annual vaccine?

Todays flu vaccines need to be adapted every year and, consequently, they must also be administered again every year. The external structure of the flu virus mutates regularly, giving rise to new strains of flu. Due to these frequent mutations, the virus is able to elude the antibodies that have been built up during a previous infection or vaccination. This is why we run the risk of catching the flu each year and also why a new flu vaccine must be developed each year. A universal flu vaccine that provides broad and lifelong protection - like the vaccines we have for polio, hepatitis B or measles - is not yet available.

Universal flu vaccine

In the 1990s, VIB researchers connected to Ghent University, under
'"/>

Contact: Evy Vierstraete
info@vib.be
329-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
17-Jul-2007


Page: 1 2

Related biology news :

1. Universal design tackles little things with big impact
2. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
3. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
4. Handicapping tuberculosis may be the way to a better vaccine
5. Developing a more effective vaccine for tuberculosis
6. New target for HIV/AIDS drugs and vaccine discovered
7. Genomic analysis uncovers new targets for HIV vaccine
8. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
9. From clinical cancer research: rethinking therapeutic cancer vaccine trials
10. Paving the way toward a vaccine against Alzheimers disease
11. Mucosal-surface immune function discoveries could boost vaccine research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/2/2019)... ... November 01, 2019 , ... Stay on top of current ... device industries. Access to all webinars is free, so be sure to register today ... , Visit http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , ...
(Date:10/30/2019)... Va. (PRWEB) , ... October 30, 2019 , ... ... offering from the Farm Credit Knowledge Center in which participants will learn about ... industry best practice relating to these technologies. , Participants will have the ...
(Date:10/30/2019)... ... October 30, 2019 , ... Amberdata Inc., the ... firms, including Fenbushi Capital, DF Capital, Rising Tide Fund, and HWVP. The ... to further accelerate its position as the leading data provider of institutional-grade blockchain ...
Breaking Biology News(10 mins):
(Date:10/22/2019)... , ... October 22, 2019 , ... ... has announced that its lead program, DBI-001, met its primary safety endpoints, with ... labeled phase 2a clinical trial for the treatment of interdigital tinea pedis (athlete’s ...
(Date:10/17/2019)... ... October 16, 2019 , ... ... easy-to-understand, web-based genetic counseling information, has published a new white paper that explores ... and provides guidance as to how patients and medical providers can be kept ...
(Date:10/10/2019)... Md. (PRWEB) , ... October 09, 2019 , ... ... announced Amy Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a newly-confirmed keynote ... 27–30 October 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist ...
(Date:10/10/2019)... (PRWEB) , ... October 10, 2019 , ... R3 Stem ... The next course is October 18-19th, 2019 in Las Vegas with spots still open. ... He completed training at several Ivy League universities including Cornell, Harvard and Dartmouth. He ...
Breaking Biology Technology:
Cached News: